India Drug Leaders Eye First-To-File In U.S. As Drugs Go Off-Patent
This article was originally published in PharmAsia News
Executive Summary
India's major drug makers such as Dr. Reddy's Laboratories, Glenmark, Lupin and Sun Pharmaceutical Industries can be expected to take advantage of $50 billion worth of U.S. drug patents going off-patent over the next five years.